Tze-Ming Chen, MD
Pulmonary Disease · San Francisco, CANPI 1215092705
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $15,975 of the $16,737 with a category attached, or 95.4%. Seagen Inc. accounts for 95.4% of it on its own, with 9 other manufacturers making up the rest. Reporting peaked in 2022 at $8,325 and has fallen 99.3% since, to $56 in 2023.
Across 19 payments — averaging $880.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Seagen Inc.$16K
- Pfizer$500
- Electromed, Inc.$67
- Pulmonx Corporation$56
- GSK$33
- Vertex$31
- plus $75 from 4 others
Across 4 payments — averaging $1746.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Gyrus ACMI, Inc.$5K
- Spiration, Inc.$2K
What the payments were for
- Consulting fees$15,97595%
- Speaking & faculty fees$5003%
- Food & beverage$2622%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Seagen Inc. | 6 | $15,975 |
| Pfizer | 1 | $500 |
| Electromed, Inc. | 4 | $67 |
| Pulmonx Corporation | 1 | $56 |
| GSK | 2 | $33 |
| Vertex | 1 | $31 |
| Advanced Respiratory, Inc | 1 | $23 |
| Chiesi USA, Inc. | 1 | $18 |
| Merck | 1 | $18 |
| Bayer | 1 | $16 |
How this compares
$16,737 in reported general payments places this provider in the 85th percentile of 1,261 pulmonary disease providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other pulmonary disease in San Francisco
- Nicholas KolaitisSan Francisco$122K
- Samuel LouieSacramento$2.8M
- Shyamsunder SubramanianTracy$1.5M
- Toby MaherLos Angeles$1.3M
- Rajkumar DasguptaPasadena$930K
- Hoang leFountain Valley$814K
- Kevin FussellEncinitas$788K
- Revati ShreeniwasStanford$726K
- David PhamWestminster$571K
- Vijay BalasubramanianFresno$529K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.